IntroductionAdvances in primary prophylaxis have resulted in improved outcomes for patients with sickle cell anemia (SCA; i.e., hemoglobin SS- and Sβ0-thalassemia). Standard prophylactic measures include a first pneumococcal polysaccharide vaccine (PPV) and transcranial Doppler ultrasound (TCD) at age 2 years. Though efficacious, evidence suggests that delivery of these interventions is suboptimal. This study reports adherence to these measures and examines concordance across various data sources, using Registry and Surveillance for Hemoglobinopathies project data.MethodsRetrospective database and SCA center chart review identified children with SCA aged 24–36 months between January 1, 2004, and December 31, 2008. PPV and TCD administration...
IntroductionThis study examined hydroxyurea usage in young children with sickle cell anemia within N...
The high childhood mortality and life-long complications associated with sickle cell anemia (SCA) in...
This study describes hydroxyurea use among children ages 1 to 17 with sickle cell anemia (SCA) enrol...
IntroductionAdvances in primary prophylaxis have resulted in improved outcomes for patients with sic...
BACKGROUND: Antibiotic prophylaxis is a mainstay in sickle cell disease management. However, adheren...
Objectives: Sickle cell disease (SCD), an inherited hemoglobinopathy that causes anemia, severe pain...
BackgroundChildren with sickle cell anemia and sickle cell trait are at an increased risk of invasiv...
Stroke, a devastating complication of sickle cell anemia (SCA), can cause irreversible brain injury ...
BACKGROUND: People affected with sickle cell disease are at high risk of infection from Haemophilus ...
ObjectiveTo develop, test, and validate the performance of ICD‐10‐CM claims‐based case definitions f...
IntroductionDespite universal newborn screening (NBS), children in the U.S. continue to experience m...
Background: Sickle cell disease (SCD) is endemic in non-Western countries. Due to migration, the pre...
OBJECTIVES: Describe rates of adherence for sickle cell disease (SCD) medications, identify patient ...
A rapid test to identify patients with sickle cell disease could have important benefits in low-reso...
FCT_UIDB/05608/2020. FCT_UIDP/05608/2020.Introduction: Sickle cell disease (SCD), an inherited haemo...
IntroductionThis study examined hydroxyurea usage in young children with sickle cell anemia within N...
The high childhood mortality and life-long complications associated with sickle cell anemia (SCA) in...
This study describes hydroxyurea use among children ages 1 to 17 with sickle cell anemia (SCA) enrol...
IntroductionAdvances in primary prophylaxis have resulted in improved outcomes for patients with sic...
BACKGROUND: Antibiotic prophylaxis is a mainstay in sickle cell disease management. However, adheren...
Objectives: Sickle cell disease (SCD), an inherited hemoglobinopathy that causes anemia, severe pain...
BackgroundChildren with sickle cell anemia and sickle cell trait are at an increased risk of invasiv...
Stroke, a devastating complication of sickle cell anemia (SCA), can cause irreversible brain injury ...
BACKGROUND: People affected with sickle cell disease are at high risk of infection from Haemophilus ...
ObjectiveTo develop, test, and validate the performance of ICD‐10‐CM claims‐based case definitions f...
IntroductionDespite universal newborn screening (NBS), children in the U.S. continue to experience m...
Background: Sickle cell disease (SCD) is endemic in non-Western countries. Due to migration, the pre...
OBJECTIVES: Describe rates of adherence for sickle cell disease (SCD) medications, identify patient ...
A rapid test to identify patients with sickle cell disease could have important benefits in low-reso...
FCT_UIDB/05608/2020. FCT_UIDP/05608/2020.Introduction: Sickle cell disease (SCD), an inherited haemo...
IntroductionThis study examined hydroxyurea usage in young children with sickle cell anemia within N...
The high childhood mortality and life-long complications associated with sickle cell anemia (SCA) in...
This study describes hydroxyurea use among children ages 1 to 17 with sickle cell anemia (SCA) enrol...